Vyne Therapeutics Inc (VYNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Sales | 135 | 99 | 6 | 167 | 126 |
| Gross Profit | 135 | 99 | 6 | 167 | 126 |
| Operating Expenses | 10,453 | 5,974 | 7,990 | 9,500 | 8,413 |
| Operating Income | -10,318 | -5,875 | -7,984 | -9,333 | -8,287 |
| Other Income | 280 | 263 | 236 | 78 | 52 |
| Pre-tax Income | -10,038 | -5,612 | -7,748 | -9,255 | -8,235 |
| Net Income Continuous | -10,038 | -5,612 | -7,761 | -9,255 | -8,235 |
| Net Income Discontinuous | -20 | -10 | -2,184 | -204 | -241 |
| Net Income | $-10,058 | $-5,622 | $-9,945 | $-9,459 | $-8,476 |
| EPS Basic Total Ops | -3.09 | -1.74 | -3.22 | -2.94 | -2.63 |
| EPS Basic Continuous Ops | -3.08 | -1.74 | -2.38 | -2.88 | -2.56 |
| EPS Basic Discontinuous Ops | -0.01 | 0.00 | -0.84 | -0.06 | -0.07 |
| EPS Diluted Total Ops | -3.09 | -1.74 | -3.22 | -2.94 | -2.63 |
| EPS Diluted Continuous Ops | -3.08 | -1.74 | -2.38 | -2.88 | -2.56 |
| EPS Diluted Discontinuous Ops | -0.01 | 0.00 | -0.84 | -0.06 | -0.07 |
| EBITDA(a) | $-10,318 | $-5,875 | $-8,139 | $-9,162 | $-8,275 |